CTRI/2019/01/017122
Active, not recruiting
Phase 4
A Phase IV Clinical Trial to evaluate safety and efficacy of Glenmark Aprezo�® (Apremilast) Tablets in subjects with Active Psoriatic Arthritis
Overview
- Phase
- Phase 4
- Intervention
- Not specified
- Conditions
- Health Condition 1: L405- Arthropathic psoriasis
- Sponsor
- Glenmark Pharmaceuticals Ltd
- Status
- Active, not recruiting
- Last Updated
- 3 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Patients who meet ALL the following criteria can be enrolled:
- •1\.Males or females, aged ââ?°Â¥ 18 years and ââ?°Â¤ 65 years at time of informed consent.
- •2\.Subjects having a diagnosis of Psoriatic Arthritis (PsA, by any criteria) for ââ?°Â¥ 6 months duration.
- •3\.Subjects meeting the Classification Criteria for Psoriatic Arthritis (CASPAR) criteria for PsA at time of screening.
- •4\.May not have axial involvement alone
- •5\.Treatment naÃ?¯ve patients or patients taking concurrent DMARDs at baseline could continue stable doses of methotrexate (ââ?°Â¤ 25 mg/week), leflunomide (ââ?°Â¤ 20 mg/day), sulfasalazine (ââ?°Â¤ 2 g/day)
- •6\.Must have ââ?°Â¥ 3 swollen AND ââ?°Â¥ 3 tender joints.
- •7\.Female subjects of child bearing potential must use medically accepted form of contraception
- •8\.Patients on stable dose of NSAIDs, narcotics and low dose oral corticosteroids (prednisone ââ?°Â¤ 10 mg or equivalent) allowed.
- •9\.Must have psoriasis of body surface area (BSA: ââ?°Â¥3%).
Exclusion Criteria
- •Exclusion Criteria
- •Patients who meet AT LEAST one of the following exclusion criteria will be excluded:
- •1\.Pregnant or lactating women or planning to become pregnant during the study period.
- •2\.History of allergy to any component of the investigational product
- •3\.Subjects with known positive human immunodeficiency virus (HIV), or have congenital or acquired immunodeficiency, hepatitis B or C
- •4\.Therapeutic failure on \> 3 agents for PsA or \> 1 biologic tumour necrosis factor (TNF) blocker, IL\-17 inhibitors discontinued within 3 months of screening.
- •5\.History of significant or current evidence of chronic infectious disease, system disorder, organ disorder, or other medical condition that would place patient at undue risk by participation or could jeopardize the integrity of the study evaluations
- •6\.Subjects with uncontrolled hypertension or recurrent hypotensive events considered as clinically relevant or documented orthostatic hypotension
- •7\.Subjects with a history or known diagnosis of uncontrolled diabetes mellitus or requiring insulin treatment
- •8\.Subjects with recent history or who are currently known to abuse alcohol or drugs
Outcomes
Primary Outcomes
Not specified
Similar Trials
Completed
Phase 4
A Post Marketing study of VELSEAL to control the bleeding from severely bleeding wounds due to accidents, trauma cases and deep arterial wounds.Health Condition 1: T888- Other specified complications of surgical and medical care, not elsewhere classifiedHealth Condition 2: null- Patients who require haemostasis control for traumatic injuries, both venous and arterial bleeds.CTRI/2018/03/012373Datt Mediproducts Pvt Ltd101
Active, not recruiting
Phase 4
Eye drops in Indian Subjects to treat dry eyeHealth Condition 1: H049- Disorder of lacrimal system, unspecifiedCTRI/2022/03/041175Alcon Research Ltd177
Active, not recruiting
Phase 1
A Phase IV Clinical Trial to Evaluate the Safety and Tolerability of ZOSTAVAX™ in Subjects =60 Years of AgeHerpes ZosterMedDRA version: 9.1 Level: LLT Classification code 10019974 Term: Herpes zosterEUCTR2007-000343-10-GBMerck & Co. Inc.12,000
Withdrawn
Phase 4
A Phase IV Clinical Trial to Evaluate the Safety and Tolerability of ZOSTAVAX in Subjects >=60 Years of AgeHerpes Zostershingles10047438NL-OMON31293Merck750
Active, not recruiting
Not Applicable
A Phase IV Clinical Trial to Evaluate the Safety and Tolerability of ZOSTAVAX™ in Subjects =60 Years of AgeEUCTR2007-000343-10-DEMerck & Co., Inc.12,000